Market Overview
Size, productivity, and herd-health economics
- Brevintel analysis values the livestock therapeutics and vaccines market at USD 18.2 billion in 2025 ($18.2B), rising to USD 19.4 billion in 2026 and USD 31.5 billion by 2035 ($31.5B) at a 5.10% CAGR.
- Demand is tied to protecting productive animals, not herd expansion alone: prevention preserves output while treatment remains necessary when biosecurity or diagnosis fails.
- Zoetis led with over 15.5% market share in 2025; Zoetis, Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Ceva Santé Animale held 59.5% combined.
- Industry data suggests animal diseases cause losses equivalent to about 20% of global animal production each year, while food production may need to rise by roughly 70% by 2050.
- Livestock contributes approximately 40% of global agricultural GDP, linking animal-health spend to food-system resilience.
- Global cattle exceed 1.5 billion head and the chicken population reached about 26.56 billion birds in 2022, creating large species-specific health needs.
- Global milk output of 965.7 million tonnes in 2023 underscores dairy exposure to mastitis, respiratory disease, parasites, and reproductive disorders.
- Aquaculture already supplies more than half of aquatic animals produced for human consumption, expanding the fish-health addressable base.
Prevention versus intervention mix
- Therapeutics held 60.86% of 2025 revenue and are projected to grow at a 5.10% CAGR through 2035, reflecting ongoing need to manage active disease and production disorders.
- Vaccines held 39.14% of 2025 revenue and are projected to expand at a 6.10% CAGR as producers shift toward planned prevention.
- Brevintel analysis sees durable advantage for suppliers that make prevention practical via cold-chain fit, dosing convenience, and veterinary-protocol integration.
- Commercial value shifts toward solutions that cut biological risk and operational disruption as disease control links to trade continuity and antimicrobial stewardship.
Market Dynamics
Key drivers
- African swine fever has affected more than 50 countries, illustrating cross-border livestock disease risk that forces organized control spending.
- Foot-and-mouth disease is endemic in areas containing more than 77% of the global livestock population, sustaining surveillance and preventive vaccination demand.
- Rising milk, meat, and egg output creates recurring incentives to protect feed conversion, fertility, milk yield, and flock or herd survival.
- Larger operations need products that fit planned herd-health protocols, efficient administration, and veterinary oversight for repeat use.
- Antimicrobial resistance ranks among the top 10 global public-health threats, reinforcing selective treatment and stronger prevention programs.
- More than 60% of emerging infectious diseases in humans originate in animals, raising the relevance of early detection and controlled antimicrobial use.
- Intensification in poultry and swine raises the cost of disease spread and supports standardized vaccination schedules and formal veterinary engagement.
- As aquaculture becomes more commercially managed, fish-health programs can move from reactive treatment toward structured prevention.
Key restraints
- Antimicrobial stewardship can constrain sales of undifferentiated anti-infectives where rules or buyers limit routine or non-judicious use.
- Producers may need veterinary supervision, diagnostics, and longer planning cycles before administering certain medicines, raising compliance costs.
- Suppliers must preserve necessary treatments while expanding vaccines, antiparasitics, diagnostics, and prevention alternatives.
- Approval requirements lengthen development timelines and raise evidence costs, especially for novel biologics and long-acting formulations.
- Cold-chain conditions, veterinary capacity, and producer protocol adherence determine whether approved products achieve commercial scale.
- Brevintel analysis finds regulation reshapes product mix rather than simply suppressing spend: therapeutics remain indispensable where prevention is uneven.
Segmentation Analysis
Product type
- Therapeutics accounted for 60.86% of 2025 revenue and are projected to grow at a 5.10% CAGR through 2035.
- The therapeutic mix includes antibiotics and anti-infectives, antiparasitics, anti-inflammatories, corticosteroids, tranquilizers, cardiovascular, gastrointestinal, and other agents.
- Vaccines accounted for 39.14% of 2025 revenue and are projected to expand at a 6.10% CAGR.
- Live attenuated, inactivated, recombinant and subunit, toxoid, and other formats address different disease risks and production settings.
- Recombinant, subunit, vector-based, and emerging mRNA platforms broaden options for difficult targets without instantly replacing established vaccines.
- Long-acting injectable therapeutics reduce repeat handling where labor and animal stress constrain adherence.
Animal type
- Cattle represented 34.56% of the market in 2025 and are projected to grow at a 5.40% CAGR, supported by dairy and beef economics.
- Poultry accounted for 26.41% of 2025 revenue and are projected to grow at a 5.90% CAGR amid large flock populations and rapid disease spread risk.
- The global chicken population of approximately 26.56 billion birds in 2022 illustrates vaccination-logistics scale.
- Swine represented 21.18% of 2025 revenue and are projected to grow at a 5.60% CAGR as African swine fever elevates biosecurity and prevention spend.
- Sheep and goats accounted for 7.05% of 2025 revenue and are projected to advance at a 6.50% CAGR.
- Aquaculture represented 8.32% of 2025 revenue and is projected to grow at a 6.20% CAGR, contingent on species biology and scalable administration.
- Other animal types held 2.47% of 2025 revenue and are projected to grow at a 5.20% CAGR.
Disease indication and route of administration
- Bacterial disease demand balances targeted anti-infectives with stewardship, diagnostics, vaccines, and practices that cut recurrence.
- Viral risks such as foot-and-mouth disease and African swine fever can reshape procurement across entire production systems.
- Parasitic disease sustains antiparasitic demand where grazing, climate, vectors, and resistance management set treatment frequency.
- Injectable parenteral routes matter for vaccines, anti-infectives, antiparasitics, anti-inflammatories, and reproductive medicines needing controlled dosing.
- Long-acting injectables may cut repeat handling, but adoption depends on price, withdrawal rules, labor, and sustained clinical confidence.
- Oral feed or water delivery suits large groups; topical products address external parasites; intranasal routes offer disease- and species-specific advantages.
Distribution channel
- Veterinary hospital pharmacies held 46.01% of 2025 distribution-channel revenue and are projected to grow at a 5.10% CAGR.
- Retail pharmacies accounted for 34.63% of 2025 revenue and are projected to grow at a 5.70% CAGR for routine and repeat purchases.
- E-commerce represented 13.28% of 2025 revenue and is projected to expand at a 5.40% CAGR, subject to regulation, fulfillment, and cold-chain needs.
- Other distribution channels accounted for 6.07% of revenue and are projected to grow at a 4.90% CAGR.
- Brevintel analysis finds segment winners combine efficacy with practical delivery formats and clear prevention or treatment protocols.
Regional Outlook
North America and Europe
- North America accounted for 40.01% of global revenue in 2025 and is projected to grow at a 5.45% CAGR through 2035.
- The regional market is expected to rise from USD 7,270.0 million in 2025 to USD 9,709.7 million in 2030 and USD 12,334.4 million in 2035.
- The United States represented 91.11% of North American revenue in 2025 and is projected to grow at a 5.70% CAGR.
- Canada accounted for 8.89% of North American revenue and is projected to grow at a 6.30% CAGR.
- U.S. cattle and calves inventory was 86.7 million head as of January 1, 2025.
- In North America, veterinary hospital pharmacies held 46.01% of 2025 channel revenue versus retail 34.63%, e-commerce 13.28%, and other 6.07%.
- Europe represented 26.20% of global revenue in 2025 and is projected to grow at a 5.60% CAGR under preventive-health and responsible-use rules.
- In 2024 the European Union had 132 million pigs, 72 million bovine animals, and 67 million sheep and goats.
- Germany had approximately 10.5 million cattle in 2024; the United Kingdom, France, Spain, Italy, and the Netherlands add distinct livestock mixes.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific accounted for 22.09% of global revenue in 2025 and is projected to post the fastest regional CAGR at 6.20%.
- China produced approximately 96.63 million tonnes of meat in 2024, underscoring the scale of food-animal production.
- China, Japan, India, Australia, and South Korea span large protein systems, expanding disease-control programs, and established veterinary infrastructure.
- Latin America represented 7.81% of global revenue in 2025 and is projected to grow at a 5.90% CAGR.
- Brazil's cattle herd reached approximately 238.6 million head in 2023, elevating preventive disease, parasite, and reproductive-health needs.
- Mexico and Argentina broaden regional opportunity across cattle, poultry, and swine systems.
- Middle East and Africa accounted for 3.89% of global revenue in 2025 and are projected to grow at a 5.10% CAGR.
- Saudi Arabia's livestock population exceeded 22 million head in 2023, with sheep and goats accounting for the majority.
- South Africa and the United Arab Emirates add differing production structures, import exposure, and animal-health infrastructure.
Competitive Landscape
Structure and recent developments
- Competition mixes multinational animal-health companies with specialized suppliers across product, species, and regional needs.
- Zoetis led with over 15.5% share in 2025; the top five held 59.5%.
- Differentiation depends on combining product development with reliable commercialization, field delivery, and regulatory evidence.
- As stewardship raises prevention value, firms with both vaccine and therapeutic capabilities can sell a broader herd-health pathway.
- On January 16, 2025, Ceva Animal Health and Touchlight licensed doggybone DNA technology for animal-health vaccines and therapeutics.
- In 2025, Vaxxinova received USDA authorization to import Vaxxon SHS, a live attenuated avian metapneumovirus vaccine for poultry.
- On February 25, 2025, Elanco Animal Health and Medgene agreed to commercialize Medgene's H5N1 vaccine for U.S. dairy cattle.
- That H5N1 outbreak had spread to nearly 1,000 U.S. dairy herds since March 2024, with recorded zoonotic transmission to humans.
Integrated producers
- Zoetis
- Merck Animal Health
- Boehringer Ingelheim
- Elanco Animal Health
- Ceva Santé Animale
Specialty suppliers
- Virbac
- HIPRA
- Vetoquinol
- Phibro Animal Health
- Indian Immunologicals
- Vaxxinova
- Biogénesis Bagó
- Bioveta
- Neogen Corporation
- Norbrook